Adagene (ADAG)

• Market cap: $99.4M
• 1 day: -5.8%
• 5 days: -11.72%
• 1 month: 24.85%
• 3 months: 9.33%
• 6 months: 16.57%
• Year to date: 2.43%
• 1 year: -23.27%
• 5 years: -92.96%
• 10 years: -92.96%
• Sector: Healthcare
• Industry: Biotechnology

About: Adagene Inc is a platform-driven, clinical-stage biopharmaceutical company engaged in transforming the discovery and development of novel antibody-based cancer immunotherapies. It is principally engaged in research, development, and production of monoclonal antibody drugs for cancers. The company's platform is designed to generate therapeutic antibody candidates with functional epitopes and species cross-reactivity, as highlighted by the company's immunotherapy pipeline.

Employees: 138

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

100% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 2

15% more funds holding

Funds holding: 13 [Q1] → 15 (+2) [Q2]

2% more capital invested

Capital invested by funds: $11.6M [Q1] → $11.8M (+$268K) [Q2]

0.02% less ownership

Funds ownership: 12.9% [Q1] → 12.88% (-0.02%) [Q2]

67% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 3

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $7
• Avg. target: $7
• High target: $7

2 analyst ratings

• positive: 2 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Arthur He	$7	Buy Maintained	15 Aug 2025
Leerink Partners Daina Graybosch	$7	Outperform Initiated	6 Aug 2025